Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 3/20 | 0.54 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | GLP1R | P43220 | 8/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | MMP12 | P39900 | 1/20 | 0.40 |
| ▸ | MMP14 | P50281 | 1/20 | 0.40 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16947836 | 0.89 | FOLH1 (0.48) | ALBFOLH1GLP1RNOD1 | |
| SCHEMBL16947953 | 0.89 | FOLH1 (0.48) | ALBFOLH1GLP1RNOD1 | |
| SCHEMBL13880485 | 0.88 | GLP1R (0.58) | ALBFOLH1SMN1; SMN2GLP1R | |
| SCHEMBL16638264 | 0.86 | GLP1R (0.53) | ALBFOLH1GLP1RNOD1 | |
| SCHEMBL16947837 | 0.86 | GLP1R (0.53) | ALBFOLH1GLP1RNOD1 | |
| SCHEMBL16711021 | 0.86 | GLP1R (0.53) | ALBFOLH1GLP1RNOD1 | |
| SCHEMBL16947838 | 0.86 | GLP1R (0.53) | ALBFOLH1GLP1RNOD1 | |
| SCHEMBL16947841 | 0.86 | GLP1R (0.53) | ALBFOLH1GLP1RNOD1 | |
| SCHEMBL16638314 | 0.86 | GLP1R (0.53) | ALBFOLH1GLP1RNOD1 | |
| SCHEMBL16638265 | 0.86 | GLP1R (0.53) | ALBFOLH1GLP1RNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266940-B2 | Double-acylated GLP-1 derivatives | NOVO NORDISK A/S (DK) | 2016-02-23 | — | — | US | disclosed |
| US-20140088005-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK A/S (DK) | 2014-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088005-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | GLP1R, SLC5A1, IAPP | ALB 22/4885FOLH1 2088/4885SMN1; SMN2 4123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.